Vaccine development company Novavax, headquartered in Gaithersburg, announced Monday that it expanded Phase 3 clinical trials for its COVID-19 vaccine candidate to include adolescents. The trials will include up to 3,000 youths ages 12-17 at up to 75 sites in the U.S., the company said in a press release. “Through the expansion of our PREVENT-19 […]
PREVENT-19
Engage us on Facebook
Follow us on Twitter
Tweets by @mymcmedia